Search results
Results from the WOW.Com Content Network
The signs and symptoms of hypopituitarism vary, depending on which hormones are undersecreted and on the underlying cause of the abnormality. The diagnosis of hypopituitarism is made by blood tests, but often specific scans and other investigations are needed to find the underlying cause, such as tumors of the pituitary, and the ideal treatment ...
In larger case series, the mortality was 1.6% overall. In the group of patients who were unwell enough to require surgery, the mortality was 1.9%, with no deaths in those who could be treated conservatively. [8] After an episode of pituitary apoplexy, 80% of people develop hypopituitarism and require some form of hormone replacement therapy.
However, clinical, laboratory data, and imaging can all help with the diagnosis.[8] First and foremost, patients present with symptoms of hypopituitarism and must undergo pituitary hormone function evaluation. [1] Biopsy is the only means of accurate diagnosis as no autoantigen has been discovered.
The cause of this condition in terms of secondary empty sella syndrome happens when a tumor or surgery damages the gland, this is an acquired manner of the condition. [1] patients with idiopathic intracranial hypertension will have empty sella on MRI [5] The cause of primary empty sella syndrome is a congenital defect (diaphragma sellae) [6]
Pain in cancer can be produced by mechanical (e.g. pinching) or chemical (e.g. inflammation) stimulation of specialized pain-signalling nerve endings found in most parts of the body (called nociceptive pain), or it may be caused by diseased, damaged or compressed nerves, in which case it is called neuropathic pain.
The hyponatremia caused by appropriate ADH release (from the kidneys' perspective) in both CHF and cirrhosis have been shown to be an independent poor prognostic indicator of mortality. Appropriate ADH release can also be a result of non-osmotic triggers. Symptoms such as nausea/vomiting and pain are significant causes of ADH release.
60% of patients responded with a mean 6.67 or 83% reduction of pain on the VAS pain scale (from baseline of 8.0 to 1.33) at 4-6 weeks post-procedure. 100% of this responder group had clinically meaningful pain relief at 4-6 weeks post-procedure. Trial remains on track to complete enrollment by year-end 2024
Between 40 and 80 percent of patients with cancer pain experience neuropathic pain. [1]Brain. Brain tissue itself contains no nociceptors; brain tumors cause pain by pressing on blood vessels or the membrane that encapsulates the brain (the meninges), or indirectly by causing a build-up of fluid that may compress pain-sensitive tissue.